MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

On February 23, 2022 Race Oncology Limited ("Race") reported a researcher team, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MD Anderson Cancer Center (Texas, USA), have identified a number of additional clinically translatable drug combinations that showed synergy with Zantrene when tested in Acute Myeloid Leukaemia (AML) cells (Press release, Race Oncology, FEB 23, 2022, View Source [SID1234610001]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This study1, sponsored by Race Oncology, has been published in the Journal Leukemia & Lymphoma and is entitled "Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells."

The MD Anderson team identified synergism of Zantrene and venetoclax in combination with panobinostat, decitabine, or olaparib, known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly (ADP-ribose) polymerase, respectively, in AML cells.

These combinations were found to enhance DNA damage, cleavage of Caspase 3 and PARP1, DNA fragmentation, increased ROS, and potent apoptosis activation in AML cells. Similar results were observed using mononuclear cells isolated from leukaemia patients, but not from healthy donors. The SAPK/JNK signalling pathway was strongly activated by the combination treatments, whereas the PI3K/mTOR and Wnt/b-catenin pro-survival pathways were inhibited.

Chief Scientific Officer, Dr Daniel Tillett said: "This work provides further preclinical data to support our upcoming Phase 1b/2 extramedullary AML trial in Australian and Europe, where patients will be treated with Zantrene in combination with decitabine or cytarabine. We are extremely excited about being able to quickly translate this work from the lab into the clinic, where it has the potential to help AML patients in need."